Exploiting Hydrophobic Amino Acid Scanning to Develop Cyclic Peptide Inhibitors of the SARS‐CoV‐2 Main Protease with Antiviral Activity
Chemistry – A European Journal · 2024
DOI: 10.1002/chem.202401606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, 2024. Verfasst von Katriona Harrison und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, The University of Sydney, Sydney, NSW, 2006, Australia. Hauptthemen laut MEDLINE: Peptides, Cyclic, Antiviral Agents, SARS-CoV-2, Coronavirus 3C Proteases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Australian Research Council.
Abstract (Originalsprache)
The development of novel antivirals is crucial not only for managing current COVID‐19 infections but for addressing potential future zoonotic outbreaks. SARS‐CoV‐2 main protease (M pro ) is vital for viral replication and viability and therefore serves as an attractive target for antiviral intervention. Herein, we report the optimization of a cyclic peptide inhibitor that emerged from an mRNA display selection against the SARS‐CoV‐2 M pro to enhance its cell permeability and in vitro antiviral activity. By identifying mutation‐tolerant amino acid residues within the peptide sequence, we describe the development of a second‐generation M pro inhibitor bearing five cyclohexylalanine residues. This cyclic peptide analogue exhibited significantly improved cell permeability and antiviral activity compared to the parent peptide. This approach highlights the importance of optimizing cyclic peptide hits for activity against intracellular targets such as the SARS‐CoV‐2 M pro .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry, The University of Sydney, Sydney, NSW, 2006, Australia.
- Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW, 2006, Australia.
- Research School of Chemistry, Australian National University, Canberra, ACT, 2601, Australia.
- The Kirby Institute, University of New South Wales, Sydney, NSW, 2052, Australia.
- Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, Australian National University, Canberra, ACT, 2601, Australia.
- Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.
ORCID-Profile: Sven Ullrich, Christoph Nitsche, Richard J Payne
Förderung
- Australian Research Council
Zitieren
APA
Harrison, K., Carlos, P. W., Ullrich, S., Aggarwal, A., Johansen-Leete, J., Sasi, V. M., Barter, I., Maxwell, J. W. C., Bedding, M. J., Larance, M., Turville, S., Norman, A., Jackson, C. J., Nitsche, C., & Payne, R. J. (2024). Exploiting Hydrophobic Amino Acid Scanning to Develop Cyclic Peptide Inhibitors of the SARS‐CoV‐2 Main Protease with Antiviral Activity. Chemistry – A European Journal. https://doi.org/10.1002/chem.202401606
Vancouver
Harrison K, Carlos PW, Ullrich S, Aggarwal A, Johansen-Leete J, Sasi VM, et al. Exploiting Hydrophobic Amino Acid Scanning to Develop Cyclic Peptide Inhibitors of the SARS‐CoV‐2 Main Protease with Antiviral Activity. Chemistry – A European Journal. 2024. doi:10.1002/chem.202401606
BibTeX
@article{Harrison2024,
author = {Harrison, Katriona and Carlos, Patrick W and Ullrich, Sven and Aggarwal, Anupriya and Johansen-Leete, Jason and Sasi, Vishnu Mini and Barter, Isabel and Maxwell, Joshua W C and Bedding, Max J and Larance, Mark and Turville, Stuart and Norman, Alexander and Jackson, Colin J and Nitsche, Christoph and Payne, Richard J},
title = {Exploiting Hydrophobic Amino Acid Scanning to Develop Cyclic Peptide Inhibitors of the SARS‐CoV‐2 Main Protease with Antiviral Activity},
journal = {Chemistry – A European Journal},
year = {2024},
doi = {10.1002/chem.202401606}
}
EUVIMED